Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

NeuroRX and Relief Therapeutics SA could merge, possible???

https://www.globenewswire.com/news-release/2019/09/16/1916030/0/en/Antipsychotic-Drugs-Market-Size-to-Reach-USD-20-539-5-Million-by-2026-Schizophrenia-Segment-to-Witness-Rapid-Growth-says-Fortune-Business-Insights.html

NeuroRX knows a thing or two about neurological disorders, yes??? >>>>>>>>>>>>>>>>>>>>>>

There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, and Autism Spectrum Disorders.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967653/

As per the report, the global Alzheimer's therapeutics market is expected to grow from USD 4.36 Billion in 2018 to USD 8.19 Billion by 2026, at a CAGR of 8.20% during the forecast period 2019-2026.

https://www.pharmiweb.com/press-release/2020-07-13/global-alzheimer-s-therapeutics-market-is-expected-to-grow-at-a-cagr-of-820-during-the-forecast-pe